Profound Medical Stock
Profound Medical Corp.
Company data
- Sector
- Healthcare
- Industry
- Medical - Devices
- Country
- Canada
- CEO
- Arun Swarup Menawat
- Employees
- 162
- Market cap
- $220 M
- IPO
- 29/10/2019
Profound Medical Corp., through its subsidiaries, is a commercial-stage medical technology firm specializing in the development of magnetic resonance (MR)-guided ablation solutions. These innovative procedures are designed to treat conditions such as prostate disease and uterine fibroids, as well as providing…
Profound Medical stock: price history
1D
-4.8%
1W
-12.9%
1M
+3.1%
6M
-9.6%
YTD
-23.6%
1Y
+8.1%
2Y
-21.0%
5Y
-60.0%
10Y
–
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~66% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 16/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Profound Medical stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 01/09/2026.
Ask the agents about Profound Medical
Analyst assessment of Profound Medical
PRICE TARGET LOW
US$11.00
CONSENSUS
US$11.00
MEDIAN
US$11.00
PRICE TARGET HIGH
US$11.00
0
STRONG BUY
6
BUY
1
HOLD
0
SELL
0
STRONG SELL
7
TOTAL · Buy
As of: 07/01/2026
Profound Medical stock metrics
P/E
-6.22
P/B
4.41
EV/EBITDA
-5.68
RETURN ON EQUITY
-19.2%
NET MARGIN
-384.2%
DEBT/EQUITY
0.15
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
97.0%
FLOAT SHARES
35,419,196
AVG. DAILY VOLUME (30D)
271,482
Attention
Price since yesterday: -4.8%
Search (Google Trends)
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Profound Medical stock
What does Profound Medical do?
Profound Medical Corp. is a company in the Healthcare sector, Medical - Devices industry, headquartered in Canada.
The CEO is Arun Swarup Menawat, the company employs around 162 people.
The IPO was on 29/10/2019; the stock trades on NASDAQ under the ticker PROF.
What do analysts say about Profound Medical stock?
7 analysts rate the stock, the consensus is Buy (as of 07/01/2026).
The average price target is US$11.00, ranging from US$11.00 to US$11.00, with a median of US$11.00.
This is an external assessment, not a statement by Market Jury.
When does Profound Medical report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly 66% stronger than usual.
Does Profound Medical pay a dividend?
No, Profound Medical currently does not pay a dividend.
Which stocks are comparable to Profound Medical?
Comparable stocks include Abbott Laboratories, Medtronic, Stryker, Boston Scientific, Edwards Lifesciences, Siemens Healthineers, DexCom and GE HealthCare Technologies.
How can I get Profound Medical stock analyzed?
Clicking "Analyze stock" lets five strategies assess Profound Medical against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.